Business Context and Reporting Period
This Form 8-K filing by DarioHealth Corp. (an emerging growth company) reports a material definitive agreement and unregistered sales of equity securities. The report date is August 22, 2017, covering events occurring between August 16, 2017, and August 22, 2017.
Key Financial Metrics and Transaction Details
The Company completed a concurrent placement offering (the "Offering") with 23 accredited and non-U.S. investors. The transaction details are as follows:
- Common Stock Issued: 483,333 shares at $1.80 per share.
- Series B Convertible Preferred Stock Issued: 2,307,654 shares at $1.80 per share.
- Total Gross Proceeds: Approximately $4.99 million (calculated from 2,790,987 total shares at $1.80).
- Transaction Costs: $140,000 placement agent commission; $35,100 finder's fee; issuance of 159,333 shares of Common Stock to finders.
- Liquidity Impact: The filing does not provide pre-offering cash balances or post-offering liquidity metrics.
Material Changes and Terms
The Offering introduces new capital and alters the capital structure with the following terms for the Series B Preferred Stock:
- Conversion: Convertible into Common Stock at $1.80 per share upon stockholder approval. No price-based anti-dilution adjustments, but includes stock-based anti-dilution protection.
- Dividends: 6% annual dividend payable in Common Stock upon automatic conversion.
- Liquidation Preference: Equal to the investment amount, applicable in deemed liquidation events such as a change in control.
- Voting Rights: Holders do not possess voting rights.
- Registration: The Company agreed to file a registration statement for resale of the securities within 60 days of closing.
Outlook, Risks, and Contingencies
The filing contains standard forward-looking statements cautioning that actual results may differ materially from expectations. Key contingencies include:
- Stockholder Approval: Conversion of Series B Preferred Stock is contingent upon obtaining stockholder approval.
- Regulatory Compliance: The Company must file a registration statement within 60 days to allow resale of the securities.
- Market Risks: General risks associated with emerging growth companies and the healthcare technology sector as discussed in prior SEC filings.
Investor Verification Checklist
- Verify the receipt of gross proceeds and the net cash impact after deducting the $175,100 in fees and the value of finder shares.
- Confirm the timeline for the filing of the registration statement for resale of the securities (due within 60 days of August 22, 2017).
- Monitor upcoming stockholder meetings for the required approval to convert Series B Preferred Stock.
- Review the Company's cash runway and burn rate in subsequent filings to assess the sufficiency of the raised capital.